Cadence Pharmaceuticals

Developing and commercializing Ofirmev, a non-opioid therapeutic for post-operative pain

Cadence was a hospital-focused, specialty pharmaceuticals company developing and commercializing Ofirmev, the first and only IV formulation of acetaminophen for mild-to-moderate pain. Cadence achieved FDA approval for Ofirmev in 2011 and launched the drug to provide post-operative hospital patients a new non-opioid therapy for pain. Ofirmev generated >$100M in sales in its third year of launch, and Cadence was acquired by Mallinckrodt in 2014.

Status

IPO in 2006; Acquired by Mallinckrodt Pharmaceuticals in 2014

Year of Investment

2006

Strategy

Life Sciences

Subsector

Specialty Pharmaceuticals

Location

San Diego, California